← Back to Screener
Artiva Biotherapeutics, Inc. Common Stock (ARTV)
Price$12.11
Favorite Metrics
Price vs S&P 500 (26W)199.35%
Price vs S&P 500 (4W)51.07%
Market Capitalization$224.92M
All Metrics
Book Value / Share (Quarterly)$4.47
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-49.95%
Cash Flow / Share (Quarterly)$-3.23
Price vs S&P 500 (YTD)109.48%
EPS (TTM)$-3.43
10-Day Avg Trading Volume0.27M
EPS Excl Extra (TTM)$-3.43
EPS (Annual)$-3.43
ROI (Annual)-76.23%
Cash / Share (Quarterly)$4.39
ROA (Last FY)-64.05%
EBITD / Share (TTM)$-3.57
ROE (5Y Avg)-59.61%
Cash Flow / Share (Annual)$-3.23
P/B Ratio2.05x
P/B Ratio (Quarterly)0.96x
Net Income / Employee (Annual)$-1
ROA (TTM)-52.38%
EPS Incl Extra (Annual)$-3.43
Current Ratio (Annual)8.61x
Quick Ratio (Quarterly)8.26x
3-Month Avg Trading Volume0.77M
52-Week Price Return364.29%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)896.10x
Asset Turnover (Annual)0.00x
52-Week High$9.16
EPS Excl Extra (Annual)$-3.43
26-Week Price Return203.33%
Quick Ratio (Annual)8.26x
13-Week Price Return86.48%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.61x
Enterprise Value$198.265
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-26045.02%
Cash / Share (Annual)$4.39
3-Month Return Std Dev100.33%
Net Income / Employee (TTM)$-1
ROE (Last FY)-76.26%
EPS Basic Excl Extra (Annual)$-3.43
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.43
Receivables Turnover (Annual)0.49x
ROI (TTM)-60.19%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)334.46%
Year-to-Date Return112.12%
5-Day Price Return33.82%
EPS Normalized (Annual)$-3.43
ROA (5Y Avg)-41.80%
Net Profit Margin (Annual)-26045.02%
Month-to-Date Return41.30%
EBITD / Share (Annual)$-3.57
Operating Margin (Annual)-26805.58%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-59.59%
EPS Basic Excl Extra (TTM)$-3.43
P/B Ratio (Annual)0.96x
Book Value / Share (Annual)$4.47
Price vs S&P 500 (13W)85.79%
Beta2.60x
Revenue / Share (TTM)$0.00
ROE (TTM)-60.22%
52-Week Low$1.47
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ARTVArtiva Biotherapeutics, Inc. Common Stock | — | — | — | — | $12.11 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Artiva Biotherapeutics develops allogeneic NK cell therapies designed to treat hematologic malignancies and solid tumors. The company's lead program, AlloNK, is an off-the-shelf, cryopreserved NK cell therapy engineered to enhance the antibody-dependent cellular cytotoxicity of monoclonal antibodies. Its pipeline also includes CAR-NK cell candidates (AB201 and AB205) supported by both internal and collaborative funding.